Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7939502 | CHIESI | Optimised formulation of tobramycin for aerosolization |
Jun, 2022
(7 months ago) | |
US6987094 | CHIESI | Optimized formulation of tobramycin for aerosolization |
Sep, 2022
(4 months ago) | |
US7696178 | CHIESI | Optimised formulation of tobramycin for aerosolization |
Sep, 2022
(4 months ago) |
Drugs and Companies using TOBRAMYCIN ingredient
Market Authorisation Date: 12 October, 2012
Treatment: Management of cystic fibrosis patients
Dosage: SOLUTION;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8455524 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(4 years from now) | |
US7659291 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(4 years from now) | |
US10758616 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(4 years from now) | |
US7612102 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(4 years from now) | |
US9364564 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(4 years from now) |
Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 1992
Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof
Dosage: INJECTABLE;INJECTION; INJECTABLE;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11103490 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(8 years from now) | |
US10010537 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(8 years from now) | |
US8658676 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(8 years from now) |
Drugs and Companies using CLEVIDIPINE ingredient
Market Authorisation Date: 01 August, 2008
Treatment: NA
Dosage: EMULSION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8703156 | CHIESI | Liquid formulation for deferiprone with palatable taste |
Oct, 2029
(6 years from now) | |
US10940115 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(15 years from now) | |
US10780055 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(15 years from now) | |
US10940116 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(15 years from now) | |
US11357731 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(15 years from now) | |
US11458103 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(15 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Apr 30, 2024 |
Drugs and Companies using DEFERIPRONE ingredient
Market Authorisation Date: 09 September, 2015
Treatment: Method of treating transfusional iron overload
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6130208 | CHIESI | Formulation containing a nucleotide analogue |
Jun, 2023
(4 months from now) | |
US9925265 | CHIESI | Methods of treating or preventing stent thrombosis |
May, 2029
(6 years from now) | |
US9427448 | CHIESI | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
Nov, 2030
(7 years from now) | |
US8680052 | CHIESI | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
Mar, 2033
(10 years from now) | |
US9439921 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(12 years from now) | |
US9700575 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(12 years from now) | |
US9295687 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(12 years from now) | |
US10039780 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(12 years from now) |
Drugs and Companies using CANGRELOR ingredient
Market Authorisation Date: 22 June, 2015
Treatment: P2y12 platelet inhibitor for use as adjunct to percutaneous coronary intervention to reduce risk of various diseases/conditions in patients not treated with a p2y12 platelet inhibitor and not given a glycoprotein iib/iiia inhibitor; Method of reducing the risk of periprocedural myocardial infarction, and stent thrombosis in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and then a continuous infusion; Method of treating, reducing the incidence of, or preventing an ischemic event in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and continuous infusion of 4 ug/kg/min for at least 2 hours or the duration of the pci; Method comprising iv administration of cangrelor before pci then continuous infusion for at least 2 hours or the duration of pci and, during or after continuous infusion, administration of a loading dose of ticagrelor, or an equivalent method
Dosage: POWDER;INTRAVENOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic